GlassScriptPhysician profile
William Jefferson Terry
NPI 1134380496
$12,028.71
in general payments reported to CMS, 2019-2025
48 companies · $1,111 in 2025
The $1,111 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,738 · 2020: $448 · 2021: $370 · 2022: $2,775 · 2023: $1,141 · 2024: $3,446 · 2025: $1,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,192 · Travel and Lodging: $1,495 · Education: $10.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,192.20 |
| Travel and Lodging | $1,494.77 |
| Education | $10.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,286.86 | 2019-2024 | Ams 700, Lumenis Pulse 120h |
| Procept Biorobotics Corporation | $2,135.51 | 2024-2025 | Aquabeam System |
| Micro-Tech Endoscopy USA, INC. | $1,500.00 | 2022 | |
| Coloplast Corp | $600.53 | 2019-2025 | Titan, Speedicath |
| Sumitomo Pharma America, INC. | $550.25 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $539.24 | 2019-2025 | Erleada, Akeega, Balversa |
| Medtronic, INC. | $532.27 | 2021-2024 | Interstim |
| Astellas Pharma US INC | $424.63 | 2019-2025 | Xtandi |
| Endo Pharmaceuticals INC. | $338.23 | 2019-2024 | Xiaflex, Aveed, Edex |
| Pfizer INC. | $315.60 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $284.37 | 2019-2025 | Provenge |
| Abbvie INC. | $224.92 | 2022-2023 | Botox |
| Karl Storz Endoscopy-America | $215.74 | 2020-2022 | |
| Accord Healthcare, INC. | $200.79 | 2022-2023 | |
| Antares Pharma, INC. | $197.37 | 2020-2025 | Xyosted, Nocdurna, Tlando |
Show all 47 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Terry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.